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A B S T R A C T   
Background: Right heart abnormalities and pulmonary hypertension (PH) may be secondary to chronic lung 
disease. Chronic lung disease is common in children with HIV. In the BREATHE trial (Trial registration: 
NCT02426112), azithromycin (AZM) reduced the risk of acute respiratory exacerbations in children aged 6–19 
years with HIV-associated chronic lung disease (HCLD) taking antiretroviral therapy. We assessed the possible 
effect of AZM on right heart dysfunction and/or PH in the trial. 
Methods: A standardised transthoracic echocardiogram using M-mode, two-dimensional and Doppler was per-
formed, at baseline and at completion of weight-based AZM given weekly for 48 weeks. Linear regression was 
used to compare trial arms. 
Results: A total of 169 participants (82 AZM arm; 87 placebo arm) were included. Participants in the placebo arm 
were older, median age 16.2 (13.0–18.2) vs 15.3 (12.9–17.4) years, p = 0.184 in the AZM arm. At baseline, right 
heart abnormalities (right ventricular systolic dysfunction (RVSD), dilatation, or PH) were observed in 7(4%). 
Following treatment, there was no difference in prevalence of RVSD between arms (p = 0.761). There was one 
incident case of suspected PH, and overall, no difference in pulmonary pressures. 
Conclusion: In children with HCLD, there was evidence of secondary cardiac effects, but AZM had no effect on 
right heart function. Long-term follow-up in children with HIV should be part of future research to understand 
the clinical implications of right heart abnormalities.   
1. Introduction 
Recent studies have shown a high prevalence and incidence of 
structural and functional echocardiographic abnormalities among chil-
dren with HIV [1–3]. Right heart abnormalities may be secondary to 
chronic lung disease (CLD) [4] which is common among children with 
HIV [5]. Pulmonary hypertension (PH) can develop as a complication of 
CLD causing right ventricular (RV) remodelling and subsequent right 
heart failure [4]. Impaired RV structure and/or function is associated 
with poor clinical outcomes [6]. 
Azithromycin (AZM) has both antibiotic and immunomodulatory 
properties and is used in management of a variety of chronic lung dis-
eases. We conducted a trial to investigate the impact of AZM on lung 
function and acute respiratory exacerbations (ARE) among children 
with HIV-associated CLD. We hypothesized that any beneficial effects on 
lung function and/or risk of ARE could have a secondary effect on right 
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heart function. In this paper, we report the findings of a sub-study to 
investigate the effect of AZM on prevalence of right heart dysfunction 
and PH. 
2. Methods 
The BREATHE trial (Bronchopulmonary function in response to 
azithromycin treatment for CLD in HIV-infected children, trial registra-
tion NCT02426112) is an individually-randomised double-blind, 
placebo-controlled trial conducted in Malawi and Zimbabwe. The trial 
protocol has been published elsewhere [7]. Briefly, children aged 6–19 
years, taking antiretroviral therapy (ART) for at least 6 months with CLD 
(defined as forced expiratory volume in one second (FEV1) z-score of − 1 
and lack of reversibility with salbutamol) were recruited from out-
patients HIV clinics from two public-sector hospitals in Harare, 
Zimbabwe and Blantyre, Malawi. Trial participants were randomised to 
receive weight-based weekly AZM or placebo for 48 weeks. Ethical 
approval was obtained from Medical Research Council of Zimbabwe, 
College of Medicine Research Ethics Committee and the London School 
of Hygiene and Tropical Medicine and the University of Tromso. 
Transthoracic echocardiography was performed to assess RV size and 
function and PH, at baseline and at 48 weeks. Echocardiography was 
performed according to American Society of Echocardiography guide-
lines [8]. The RV basal diameter, tricuspid annular plane systolic 
excursion (TAPSE) and right atrial (RA) area were measured. Tricuspid 
peak gradient and pulmonary arterial systolic pressure (PASP) were also 
estimated [9]. RV and RA dilatation were defined as > +2 z-score of RV 
diameter and RA area respectively, using European references [10]. RV 
systolic dysfunction (RVSD) was defined as < -2 z-score of TAPSE using 
reference equations from Zimbabwean children [11]. PH was defined as 
tricuspid regurgitation velocity ≥ 2.9 m/s and PASP ≥ 37 mmHg 
(assuming an RA pressure of 5 mmHg) [9]. 
Due to technical issues with the ultrasound machine in Malawi, the 
current sub-study could not be conducted in Malawi. Therefore, this 
study was conducted in Zimbabwe only. 
2.1. Statistical analysis 
Analyses were performed using Stata v15⋅0 software (StataCorp, 
Texas, USA). Continuous data was presented as mean ± standard devi-
ation (SD) if they were normally distributed or median (interquartile 
range, IQR) if not normally distributed. For categorical variables, the 
number and percentage in each category was reported. All continuous 
data were tested for heteroskedasticity and corrected for, prior to any 
Fig. 1. Study flow diagram.  
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regression analysis. Heteroskedasticity was assessed through visual in-
spection of residuals vs fitted values plots and Cook-Weisberg test. The 
presence of heteroskedasticity was addressed by use of robust standard 
errors. 
Linear regression was used to compare cardiac measures in the trial 
arms, to estimate the mean difference and corresponding 95% confi-
dence interval (CI), adjusting for baseline value of the cardiac measure 
as a continuous covariate, categorical age, sex, and log 10 viral load. The 
mean change in z-scores in each trial arm for the primary cardiac 
measures was calculated as mean z-score (12 months) minus mean z- 
score (baseline) and adjusted for baseline z-scores, age, sex and viral 
load using linear regression. Multivariable logistic regression was used 
to assess which covariates were associated with right heart abnormal-
ities at baseline. 
A total of 18 (10%) scans at baseline were used to estimate intra-rater 
variability for RV and RA measures using intra-class correlation coeffi-
cient (ICC). ICC values range from 0 to 1 with values above 0.75 rep-
resenting good to excellent reliability, and values below 0.75 
representing moderate to poor reliability. 
3. Results 
Of the 347 participants enrolled in the trial, 241 were enrolled from 
Zimbabwe and of these 169 (82 AZM arm; 87 placebo arm) were 
included in this sub-study. Participants excluded were missing either a 
baseline or a 48-week echocardiogram (Fig. 1). In those excluded (n =
72), there were no age or sex differences to those included the study. 
Participants in the placebo arm were older, median age 16.2 (13.0–18.2) 
vs 15.3 (12.9–17.4) years, , p = 0.184 in the AZM arm (Table 1). 
At baseline, right heart abnormalities (RVSD, RV dilatation, or PH) 
were observed in 7(4%) participants. Mean RV, RA and TAPSE z-scores 
were similar between the arms at baseline and 48 weeks (Table 2). After 
treatment with AZM, 4(5%) vs 3 (4%) of participants in the placebo and 
AZM arm respectively had RVSD (p = 0.761), of which one participant 
had RVSD at both baseline and 48 weeks. At 48 weeks, PH was suspected 
in in two participants, one in the placebo and AZM arm, respectively. 
Mean RV z-scores following treatment were higher in the placebo arm, 
+0.43 (0.8) compared to + 0.36 (0.6) in the AZM arm, but not signifi-
cantly so - adjusted mean difference of − 0.05 (95% CI using robust 
standard errors, − 0.20 to 0.09, p = 0.488). No clinical or HIV related 
factors were associated with right heart abnormalities. Left ventricular 
systolic function was similar between trial arms. 
The ICC analysis for RV basal diameter was (0.921), TAPSE (0.878) 
and for RA area (0.879), Overall ICC showed good intra-rater reliability. 
4. Discussion 
The study found that 4% of participants had right heart abnormal-
ities and were not associated with elevated right heart pressures. PH was 
rare at both baseline and 48 weeks. Although echocardiography is a 
recommended screening tool for suspected PH, doppler echocardiogra-
phy can frequently under-or overestimate pulmonary arterial pressures 
in patients [12]. Importantly, other echocardiographic signs of pH 
which may support suspicion of pH appeared to be absent or quite 
minimal in this study including enlarged right atrium, systolic flattening 
of the interventricular septum and RV dilatation. This may further 
support the rarity of this condition in this study. RV remodelling is 
typically secondary to increase in RV afterload but may occur in the 
absence of elevated pulmonary pressures [13]. 
CLD may induce altered structure and function of the right heart due 
to abnormal pulmonary function and this is often associated with PH. 
While AZM was associated with a reduction of risk of acute respiratory 
exacerbations [14], it had no effect on pulmonary function and right 
heart abnormalities. It is possible that the mechanism of the observed 
right heart abnormalities was not due to lung function impairment but, 
HIV per se may have induced the changes. We have previously reported 
an 8% prevalence of RV abnormalities in a cohort of children established 
on ART, more than half of whom had concurrent left heart abnormal-
ities, suggesting a cardiomyopathy affecting both sides of the heart [2]. 
It is also plausible that ART and viral suppression play a significant role 
in preventing clinical cardiomyopathy. All participants were on ART but 
only 58% were virally suppressed at enrollment. We acknowledge that 
follow-up time may have been too short to observe any beneficial effects 
of AZM on cardiac disease, and/or insufficient power to detect any po-
tential effects. 
Limitations of this study include lack of right heart catheterisation to 
completely rule- out PH. There is possible underestimation of pulmonary 
pressures due to the inherent limitations and operator dependency of the 
echocardiography technique. Importantly, this study was performed in a 
resource-limited setting and more advanced contemporary imaging 
measures were not available including three-dimensional echocardiog-
raphy, tissue doppler and speckle tracking imaging. Their use may have 
provided better imaging of global or regional function. However, we 
only used optimum images to acquire measurements from in this study. 
Notably, in most healthcare settings in this region, there is not wide-
spread availability of advanced echocardiographic techniques and so 
our findings will be more readily applicable to a low-resource setting, 
which is where the majority of these patients are seen. 
In summary, right heart abnormalities were observed in a small 
proportion of children with HCLD taking ART, but AZM had no impact 
on right heart size and function. Long-term follow-up in children with 
HIV should be part of future research to understand the clinical impli-
cations of right heart abnormalities. 
Table 1 
Baseline clinical characteristics of participants.  
Characteristic Azithromycin 
arm 
N = 82 
Placebo arm 
N = 87 
P- 
value 
Demographic    
Sex, female, N (%) 33 (40) 40 (46)  0.452 





HIV    
HIV VL, median log10 copies/ml, 
median (IQR) 
2.6 (1.8–3.8) 2.9 (2.1–4.2)  0.151 
VL < 1000 copies/ml, N (%) 50 (61) 48 (55)  0.445 
CD4 count, (cells/mm3), median 
(IQR) 
571 (384–736) 508 (278–740)  0.354 
CD4 count < 100, (cells/mm3), N 
(%) 
6 (7) 6 (7)  0.915 
Age at HIV diagnosis, y, median 
(IQR) 
7 (3–9) 8 (5–11)  0.061 
Age at ART start, y, median (IQR) 7 (4–10) 9 (6–12)  0.034 
Duration on ART, y, median (IQR) 4 (3–4) 4 (2–4)  0.307 
ART Regimen, n (%)    0.057 
EFV/NVP 49 (60) 64 (74)  
ATV/LPV 33 (40) 23 (26)  
Taking cotrimoxazole prophylaxis, 
n (%) 
74 (90) 79 (91)  0.901 
Clinical    
Body surface area, m2, mean (SD) 1.24 (0.23) 1.30 (0.24)  0.081 
Weight-for-age z-score, mean (SD) − 2.29 (1.43) − 2.04 (1.57)  0.294 
Underweight, n (%) 45 (55) 41 (47)  0.314 
Height-for-age z-score, mean (SD) − 2.10 (1.14) − 1.92 (1.26)  0.346 
Stunted, n (%) 42 (51) 35 (40)  0.152 
Respiratory rate, breaths/minute, 
mean (SD) 
22 (3) 22 (3)  0.668 
Heart rate, beats/minute, mean 
(SD) 
86 (13) 85 (11)  0.448 
Oxygen Saturation, (%), mean 
(SD) 
96 (3) 97 (3)  0.659 
VL, viral load; ART, antiretroviral therapy; AZM, azithromycin; SD, standard 
deviation; IQR, inter-quartile range; EFV, efavirenz; NVP, nevirapine, ATV, 
atazanavir; LPV, lopinavir. 
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Table 2 
Echocardiographic Findings at baseline and after 48 weeks.   








AZM (N = 82) Placebo (N =
87)  
Right       
RV diameter, mm b, mean (SD) 35.6 (3.6) 36.4 (3.9) 37.1 (3.7) 38.2 (3.9) − 0.21 (− 0.78–0.36) 0.469 
RV diameter z-score, mean (SD) 0.22 (0.7) 0.21 (0.6) 0.36 (0.6) 0.43 (0.8) − 0.05 (− 0.20–0.09) 0.488 
RA area cm2 b, mean (SD) 11.6 (2.1) 11.8 (2.3) 12.6 (2.3) 12.8 (2.4) − 0.22 (− 0.64–0.21) 0.312 
RA area z-score, mean (SD) 0.16 (0.9) − 0.06 (0.8) 0.34 (0.8) 0.23 (0.8) − 0.05 (− 0.23–0.14) 0.625 
TAPSE mm b, mean (SD) 20.6 (2.2) 20.8 (2.2) 20.3 (2.2) 20.6 (0.9) − 0.28 (− 0.98–0.38) 0.398 
TAPSE z-score, mean (SD) − 0.15 (1.0) − 0.11 (0.9) − 0.32 (1.0) − 0.26 (0.9) − 0.11 (− 0.39–0.18) 0.454 
Tricuspid peak gradient, mmHg b, median 
(IQR) 
5.3 (3.9–10) 4.7 (3.5–10) 5.4 (3.7–11.5) 6.4 (3.9–12.0)   
PASP mmHg, median (IQR) 10.4 (8.9–15) 10.0 (8.5–15.7) 10.7 
(8.7–18.9) 
12.0 (8.9 –17.8)   
PH, N (%) 1(1) – 1(1) 1(1)   
RV dilatation, N (%) 1(1) – – –   
RVSD, N (%) c 3 (4) 2(2) 3 (4) 4 (5)   
Left       
LV diameter z-score 0.46 (1.5) 0.69 (1.4) 0.80 (1.4) 0.91 (1.4) 0.13 (− 0.11–0.38) 0.285 
IVS diameter z-score 0.58 (1.4) 0.36 (1.5) 0.92 (1.4) 1.00 (1.5) − 0.28 (− 0.60–0.05) 0.094 
LVPW diameter z-score 0.12 (1.2) − 1.73 (1.3) 0.23 (0.9) 0.17 (1.3) − 0.04 (− 0.35–0.27) 0.805 
LV ejection fraction, % 62.6 (6.2) 63.0 (6.7) 61.6 (6.2) 61.9 (6.2)   
Cardiac symptoms       
Tachycardia, N (%) 2 (2) 1(1) 1 (1) 3 (3)  NS 
Tachypnoea, N (%) d 8 (10) 7 (8) 12 (15) 9 (10)  NS 
Hypoxia, N (%) 2 (2) 5 (6) 2 (2) –  NS 
Shortness of breath, N (%) 2 (2) 1 (1) 1(1)   NS 
AZM, azithromycin; RV, right ventricular; RA, right atrium; RVSD, right ventricular systolic dysfunction; TAPSE, tricuspid annular plane systolic excursion; PASP, 
pulmonary arterial systolic pressure; LV, left ventricular; IVS, interventricular septum; LVPW, left ventricular posterior wall; SD, standard deviation; IQR, inter-quartile 
range; NS, not significant 
a Mean difference comparing arms at 48 weeks adjusted for baseline cardiac measure, age category, sex, and viral load log10 copies/ml. 
b Missing values: RV diameter n = 3; TAPSE n = 2; RA diameter n = 10; Tricuspid peak gradient n = 9. 
c n = 1 had RVSD at baseline and 48 weeks. 
d n = 3 had tachypnoea at baseline and 48 weeks. 
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